ZENG Chun-Ying-,
,
LU Xiao-Jun- etc
.[J] Chinese Pharmaceutical Journal, 2013,V48(5): 326-330
��
[1]
KIDANI Y,NOJI M,TASHIRO T. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers[J].Gann,1980,71(5):637-643.
[2]
NOORDHUIS P,LAAN A C,BORN K V D,et al. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines[J]. Biochem Pharma,2008,76(1):53-61.
[3]
YAO Y,JIA X Y,TIAN H Y. Comparative proteomic analysis of colon cancer cells in response to Oxaliplatin treatment[J]. Biochim Biophys Acta,2009,1794(10):1433-1440.
[4]
MARTIN A,GRAHAM M A,LOCKWOOD G F,et al. Clinical pharmacokinetics of oxaliplatin: A critical review[J]. Clin Cancer Res,2000,6��4��:1205-1217.
[5]
EHRSSON H,WALLIN I,YACHNIN J. Pharmacokinetics of oxaliplatin in man—Correlation between in vivo clearance and degradation rate in whole blood. 2002. the 12th ICACT,Paris,France.
[6]
RAYMOND E,CHANEY S G,TAAMMA A,et al. Oxaliplatin: A review of preclinical and clinical studies[J]. Ann Oncol,1998,9(10):1053-1071.
[7]
VIDEHULT P,YACHNIN J,JERREMALM E,et al. Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin[J]. Cancer Lett,2002,180(2):191-194.
[8]
UPADHYAY S C. Stable oxaliplatin formulation: United state,20070054957A1 .2007-03-08.
[9]
ALBERTO M E,LUCAS M F,PAVELKA M,et al. The degradation pathways in chloride medium of the third generation anticancer drug oxaliplatin[J]. J Phys Chem B,2008,112(35):10765-10768.
[10]
LUCAS M F A,PAVELKA M,ALBERTO M E,et al. Neutral and acidic hydrolysis reactions of the third generation anticancer drug oxaliplatin[J]. J Phys Chem B,2009,113(3):831-838.
[11]
JERREMALM E,VIDEHULT P,ALVELIUS G,et al. Alkaline hydrolysis of oxaliplatin—isolation and identification of the oxalate monodentate intermediate[J]. J Pharm Sci,2002,91(10):2116-2121.
[12]
SEHGAL A. Stable oxaliplatin composition for parental administration: United state,20100267824 A1 . 2010-10-21.
[13]
ANDERSON N H. Oxaliplatin formulations: United state,6306902B1 . 2001-10-23.
[14]
WHITTAKER D V. Oxaliplatin formulation: United state,200701558 33A1 . 2007-07-05.
[15]
SAKURAI M,EGASHIRA N,KAWASHIRI T. Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia[J].Pain,2009,147(1-3):165-174.
[16]
SCHULZE C,MCGOWAN M,JORDT S E,et al. Prolonged oxaliplatin exposure alters intracellular calcium signaling: A new mechanism to explain oxaliplatin-associated peripheral neuropathy[J]. Clin Colorectal Cancer,2011,10(2):126-133.
[17]
KNIJN N,TOL J,KOOPMAN M,et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients[J]. Eur J Cancer,2011,47(3):369-374.
[18]
WHITTAKER D V,LIU A J. Acid containing oxaliplatin formulations: United state,20100063145 A1 . 2010-03-11.
[19]
ICH STEERING COMMITTEE. ICH Q1A(R2) Stability testing guidelines: Stability testing of new substances and products. 2003.
[20]
MIKATA Y,SHINOHARA Y,YONEDA K. Unprecedented sugar-dependent in vivo antitumor activity of carbohydrate-pendant cis-diamminedichloroplatinum(II) complexes[J]. Med Chem Lett, 2001,11(23):3045-3047.
[21]
JANINA M KER J,THIEM J. Synthesis and hydrolysis studies of novel glyco-functionalized platinum complexes[J]. Carbohydr Res,2012,348:14-26.
[22]
ZALUDEK B. Oxaliplatin pharmaceutical composition with alcoholic sugar-based Buffer: United state,2010093849A1 . 2010-03-15.
[23]
HE J. A synthetic process of oxaliplatin: China,200610010829.5 . 2008-07-02.
[24]
PU S P. Purification of oxaliplatin: China,03135146.8 . 2005-05-18.
[25]
KYSILKA V. Process for the preparation of oxaliplatin: United state,7872150B2. 2010-07-08.
[26]
YEN H D,JOSEPH D L. Hydroxyl radical involvement in the decomposition of hydrogen peroxide by ferrous and ferric nitrilotriacetate complexes at neutral pH[J]. Water Res,2011,45(11):3309-3317.
[27]
WANG J Y. Oxygen radicals and human health[J]. Chem World(��ѧ����),2006,47��1��:61-63.
[28]
XUE C M. An oxaliplatin drug compositions and their preparation methods:China,200810249853.3. 2009-06-24.
[29]
SAKAI K,KIZAKI Y,TSUBOMURA T,et al. Homogeneous catalysis of mixed-valent octanuclear platinum complexes in photochemical hydrogen production from water[J]. J Mol Catal,1993,79(1-3):141-152.
[30]
SAWYER D T,BRANNAN J R. Proton nuclear magnetic resonance studies of metal gluconate complexes. I. Lead(��) and bismuth(��) [J]. Inorg Chem,1996,5(1):65-70.
[31]
ZHOU Y. An oxaliplatin intravenous emulsion and its preparation method: China,200610065728.8 . 2006-11-08.
[32]
LIU W,WANG D K. Preparation of oxaliplatin phospholipids complex and nanosuspension . J Shenyang Pharm Univ(����ҩ�ƴ�ѧѧ��),2007,24(4): 197-199.
[33]
WANG D K,WANG W. Nano-miscible injection of intravenous administration of oxaliplatin phospholipid complex: China: 200610084357.8 . 2006-11-29.
[34]
ICH Q3B. International conference on harmonization of technical requirements for registration of pharmaceutical for human use. Impurities in New Drugs Products. 2006.
[35]
AMR A L,TAKUYA S,YUSUKE D,et al. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model[J]. J Controlled Release,2009,134(1):18-25.
[36]
CUI L. Preparation of oxaliplatin loaded human serum albumin nanoparticles: China,200910056627.8 . 2010-05-19.
[37]
HU F Q. Oxaliplatin chitosan - stearic acid grafted micelles and its application: China,201010141124.3. 2010-08-11.
2013, Vol. 48 
